Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceHBIO 53 Market Cap is $36.69 Mil as of Sep. 06, 2026. GuruFocus rates HBIO with a GF Score™ of 53/100 and a GF Value™ of $12.30 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 859 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 68.57% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Harvard Bioscience's share price for the quarter that ended in Jun. 2026 was $6.15. Harvard Bioscience's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 4.55 Mil. Therefore, Harvard Bioscience's market cap for the quarter that ended in Jun. 2026 was $27.99 Mil.
Harvard Bioscience's quarterly market cap
declined
from Dec. 2025 ($29.91 Mil) to Mar. 2026 ($21.96 Mil) but then
increased
from Mar. 2026 ($21.96 Mil) to Jun. 2026 ($27.99 Mil).
Harvard Bioscience's annual market cap
declined
from Dec. 2023 ($232.14 Mil) to Dec. 2024 ($92.99 Mil) and
declined
from Dec. 2024 ($92.99 Mil) to Dec. 2025 ($29.91 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Harvard Bioscience's Enterprise Value for Today is $74.40 Mil.
Harvard Bioscience (NAS:HBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Harvard Bioscience Market Cap Related Terms
Harvard Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Harvard Bioscience's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (HBIO) has a Market Cap of $36.69 Mil as of Sep. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #589 out of 859 companies in the Medical Devices & Instruments industry, placing it in the top 68.6%.
Is Harvard Bioscience's Market Cap too high?
Harvard Bioscience's current Market Cap is $36.69 Mil. The Medical Devices & Instruments industry median Market Cap is 124.95. Harvard Bioscience's value of $36.69 Mil is 70.6% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #589 out of 859 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Market Cap compare to MLSS and FEMY?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #589 out of 859 companies for Market Cap. This places Harvard Bioscience in the lower half of its industry. The industry median Market Cap is 124.95. Harvard Bioscience's value of $36.69 Mil is 70.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 124.95, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Market Cap of $36.69 Mil is 70.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 124.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Market Cap is $36.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $12.30, compared to a current price of $8.06 — trading 34.5% below its estimated fair value. The current Market Cap is $36.69 Mil and 70.6% below the Medical Devices & Instruments industry median of 124.95. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current Market Cap is $36.69 Mil as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (HBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of $8.06 is trading 34.5% below its estimated GF Value™ of $12.30.
GuruFocus considers Harvard Bioscience to be Possible Value Trap.
Key valuation signals for HBIO:
Market Cap: $36.69 Mil
GF Value™: $12.30 vs. price of $8.06 (34.5% below fair value)
Industry Position: 70.6% below the Medical Devices & Instruments median (#589 of 859)
No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for HBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBIO has been successfully added to your 
